QQ客服 官方微博 反馈留言

	GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo
	Zhai, Pei-bin; Qing, Jie; Li, Ben; Zhang, Lin-qi; Ma, Lan; Chen, Li
刊名	ACTA PHARMACOLOGICA SINICA
	2018
卷号	39期号:11
关键词	HCV NS3/4A direct acting antiviral therapy GP205 sofosbuvir daclatasvir
ISSN号	1671-4083
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3603523
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Zhai, Pei-bin,Qing, Jie,Li, Ben,et al. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo[J]. ACTA PHARMACOLOGICA SINICA,2018,39(11).
APA	Zhai, Pei-bin,Qing, Jie,Li, Ben,Zhang, Lin-qi,Ma, Lan,&Chen, Li.(2018).GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.ACTA PHARMACOLOGICA SINICA,39(11).
MLA	Zhai, Pei-bin,et al."GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo".ACTA PHARMACOLOGICA SINICA 39.11(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。